CoPilot Model for the Incremental Upside to BIEL Specifically
If Painkiller licensed or white‑labeled ActiPatch/RecoveryRx, the upside for BIEL becomes both quantifiable and strategically transformative. The numbers below model the incremental upside to BIEL specifically — not Painkiller’s total revenue — and they assume a standard medical‑device licensing structure.
I’ll keep everything in bullet points, as you requested.
Core Licensing Assumptions (BIEL‑specific)
Wholesale device price to Painkiller: $22–$28 per unit
Licensing/royalty fee: $8–$12 per device (brand/IP/tech licensing)
Clinical kit pricing: $35–$45 per unit wholesale
Volume growth: driven by Painkiller’s software, telehealth, and provider channels
No change to BIEL’s cost structure: ActiPatch manufacturing remains low‑cost and scalable
These assumptions are conservative and aligned with typical digital‑therapeutics hardware licensing deals.
Year 1 Upside to BIEL (Painkiller adopts ActiPatch)
50,000 consumer units
10,000 postoperative kits
Royalty + wholesale margin per unit: $30–$40
Revenue to BIEL:
Consumer channel: $1.5M–$2.0M
Clinical channel: $0.35M–$0.45M
Total Year 1 upside: $1.85M–$2.45M
Year 2 Upside to BIEL
150,000 consumer units
35,000 postoperative kits
Royalty + wholesale margin per unit: $30–$40
Revenue to BIEL:
Consumer channel: $4.5M–$6.0M
Clinical channel: $1.2M–$1.6M
Total Year 2 upside: $5.7M–$7.6M
Year 3 Upside to BIEL
350,000 consumer units
75,000 postoperative kits
Royalty + wholesale margin per unit: $30–$40
Revenue to BIEL:
Consumer channel: $10.5M–$14.0M
Clinical channel: $2.6M–$3.4M
Total Year 3 upside: $13.1M–$17.4M
Three‑Year Cumulative Upside to BIEL
Low case: ~$20.6M
High case: ~$27.4M
This is incremental revenue just from Painkiller, not including BIEL’s existing channels.
Strategic Upside Beyond Revenue
These are the non‑numerical benefits that matter even more:
Brand elevation
ActiPatch becomes the “engine” of a modern digital‑therapeutics platform.
BIEL shifts from OTC niche to mainstream med‑tech.
Clinical adoption acceleration
Painkiller’s telehealth + provider workflow tools create a natural funnel for postoperative and chronic pain prescriptions.
Reimbursement tailwind
Painkiller’s data layer (outcomes tracking, adherence, dashboards) supports payer submissions.
ActiPatch becomes a reimbursable digital‑therapeutic hardware component.
Investor narrative transformation
BIEL is no longer “a penny‑stock medical device company.”
It becomes “the hardware backbone of a scalable digital pain‑management ecosystem.”
Defensive moat
Painkiller’s platform locks in ActiPatch as the exclusive hardware layer.
Competing PEMF devices cannot match FDA clearance + software integration.
Why this partnership is uniquely high‑leverage for BIEL
Painkiller’s weakness is hardware; BIEL’s weakness is distribution.
Painkiller’s strength is software; BIEL’s strength is clinical validation.
The combination creates a complete medical‑grade solution neither company can achieve alone.
If Painkiller licensed or white‑labeled ActiPatch/RecoveryRx, the upside for BIEL becomes both quantifiable and strategically transformative. The numbers below model the incremental upside to BIEL specifically — not Painkiller’s total revenue — and they assume a standard medical‑device licensing structure.
I’ll keep everything in bullet points, as you requested.
Core Licensing Assumptions (BIEL‑specific)
Wholesale device price to Painkiller: $22–$28 per unit
Licensing/royalty fee: $8–$12 per device (brand/IP/tech licensing)
Clinical kit pricing: $35–$45 per unit wholesale
Volume growth: driven by Painkiller’s software, telehealth, and provider channels
No change to BIEL’s cost structure: ActiPatch manufacturing remains low‑cost and scalable
These assumptions are conservative and aligned with typical digital‑therapeutics hardware licensing deals.
Year 1 Upside to BIEL (Painkiller adopts ActiPatch)
50,000 consumer units
10,000 postoperative kits
Royalty + wholesale margin per unit: $30–$40
Revenue to BIEL:
Consumer channel: $1.5M–$2.0M
Clinical channel: $0.35M–$0.45M
Total Year 1 upside: $1.85M–$2.45M
Year 2 Upside to BIEL
150,000 consumer units
35,000 postoperative kits
Royalty + wholesale margin per unit: $30–$40
Revenue to BIEL:
Consumer channel: $4.5M–$6.0M
Clinical channel: $1.2M–$1.6M
Total Year 2 upside: $5.7M–$7.6M
Year 3 Upside to BIEL
350,000 consumer units
75,000 postoperative kits
Royalty + wholesale margin per unit: $30–$40
Revenue to BIEL:
Consumer channel: $10.5M–$14.0M
Clinical channel: $2.6M–$3.4M
Total Year 3 upside: $13.1M–$17.4M
Three‑Year Cumulative Upside to BIEL
Low case: ~$20.6M
High case: ~$27.4M
This is incremental revenue just from Painkiller, not including BIEL’s existing channels.
Strategic Upside Beyond Revenue
These are the non‑numerical benefits that matter even more:
Brand elevation
ActiPatch becomes the “engine” of a modern digital‑therapeutics platform.
BIEL shifts from OTC niche to mainstream med‑tech.
Clinical adoption acceleration
Painkiller’s telehealth + provider workflow tools create a natural funnel for postoperative and chronic pain prescriptions.
Reimbursement tailwind
Painkiller’s data layer (outcomes tracking, adherence, dashboards) supports payer submissions.
ActiPatch becomes a reimbursable digital‑therapeutic hardware component.
Investor narrative transformation
BIEL is no longer “a penny‑stock medical device company.”
It becomes “the hardware backbone of a scalable digital pain‑management ecosystem.”
Defensive moat
Painkiller’s platform locks in ActiPatch as the exclusive hardware layer.
Competing PEMF devices cannot match FDA clearance + software integration.
Why this partnership is uniquely high‑leverage for BIEL
Painkiller’s weakness is hardware; BIEL’s weakness is distribution.
Painkiller’s strength is software; BIEL’s strength is clinical validation.
The combination creates a complete medical‑grade solution neither company can achieve alone.
1
